Therapy Areas: Central Nervous System
CAMP4 Secures USD 100m series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
22 July 2022 - - US-based biotechnology company CAMP4 Therapeutics has closed a USD 100m series B round to advance the company's lead regRNA programs and accelerate the expansion of the company's regRNA Actuating Platform, the company said.

Enavate Sciences, a portfolio company created by Patient Square Capital, led the round. Additional investors in the series B financing include a large national managed care organization and the Gaingels, an LGBTQIA+/Allies investment syndicate supporting diversity in venture capital, along with other unnamed investors.

Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group, and others also joined the round.

CAMP4's approach uniquely targets regulatory RNAs, considered to be part of the "Dark Side of the Genome," the 98% of our genome that does not encode proteins.

Through breakthroughs in molecular biology, it is now known that regRNAs control the expression of nearby protein-encoding genes.

CAMP4's RNA Actuating Platform maps regRNAs associated with every protein-coding gene in any cell type, and its programmable antisense oligonucleotide therapeutics target the controlling regRNAs to upregulate gene expression to treat disease.

This approach is applicable to a range of genetic diseases in which tunable increases in gene output can lead to meaningful therapeutic outcomes.

The company expects to enter the clinic with its lead candidate to treat Dravet syndrome by mid-2023.

The financing round will further support the advancement of CAMP4's drug candidates, including progressing its urea cycle disorder program into the clinic and continuing to build an expansive pipeline of RNA actuators.

While the company is initially focusing on treating diseases of the central nervous system and liver, its platform has the potential to address a range of genetic indications across multiple tissues, with a focus on haploinsufficient diseases.